Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Mathias Lichterfeld · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2023 · $82,537 — Project Summary/Abstract, Immune Control (Project 4) Finding a cure for HIV-1 infection is of particular importance for the growing number of HIV-1-infected infants, children and teenagers who will have to take lifelong antiretroviral therapy if curative treatment options will not be available. Rece…
VICTORIA COLEMAN · LEIDOS BIOMEDICAL RESEARCH, INC. · 2023 · $7,090,787 — The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development, and clinical testing of vaccines and therapeutics for emerging and endemic infectious diseases. In 2019, in response to the COVID-19 outbreak, mRNA vaccines were quickly developed a…
Ai-ris Yonekura Collier · BETH ISRAEL DEACONESS MEDICAL CENTER · 2023 · $259,350 — PROJECT SUMMARY/ABSTRACT Pregnant individuals are more likely to require invasive mechanical ventilation or die from complications related to coronavirus disease 2019 (COVID-19) than non-pregnant women. COVID-19 vaccination in pregnancy can prevent the consequences of infection for the mother and pr…
Herman F Staats · DUKE UNIVERSITY · 2023 · $260,780 — Project Summary/Abstract: Oral immunotherapy with PALFORZIA® is a recently FDA-approved therapy to treat peanut allergy. This therapy requires daily doses of characterized peanut proteins administered orally to peanut hypersensitive individuals. A major limitation of the PALFORZIA® therapy is the po…
ROBIN J SHATTOCK · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · 2023 · $341,645 — Abstract/summary There is currently no vaccine in clinical use to combat group A streptococcal infection, despite the considerable global burden of acute and chronic disease attributable to this pathogen. The long-term goal of this work is the development of a combination vaccine that can combat gro…
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2023 · $660,767 — ABSTRACT Programming the immune system to detect neoantigens and destroy tumors is critical for effective immunotherapy. Until now, bioinformatic prediction of neoepitopes on tumors from Next Generation Sequencing (NGS) information has been used alone or in conjunction with immunological assays to i…
JAMES FRANCIS MARKMANN · MASSACHUSETTS GENERAL HOSPITAL · 2023 · $637,715 — PROJECT SUMMARY / ABSTRACT It has been suggested that the future of medicine rests in cell and gene therapy. While this assertion may be premature, it seems clear that these innovative therapies have extraordinary, paradigm shifting potential. For cell-based therapies, this is best exemplified by th…
Rhiju Das · STANFORD UNIVERSITY · 2023 · $684,690 — PROJECT SUMMARY The continuing discoveries of RNAs and their critical roles in cellular and viral machinery are inspiring novel antibacterial, antitumor, antiviral, and genome-editing therapies based on disabling, manipulating, and repurposing the RNAs involved. Unfortunately, our poor biophysical u…
Christopher C. Beyrer · IAS · 2023 · $750,000 — Project Summary IN 2021 UNAIDS estimated the HIV incidence to have been 1.5 million new infections, while the 2020 target was set to be under 500,000 global infections for that year. At this rate, the HIV response is sharply off target to achieve the goal of an end to the pandemic as the global publ…
MICHAEL ANDREW FISCHBACH · STANFORD UNIVERSITY · 2023 · $770,910 — PROJECT SUMMARY/ABSTRACT Eliciting or suppressing an adaptive immune response has become central to oncology, autoimmunity, and infectious disease. Checkpoint inhibitors have revolutionized the treatment of cancer, while TNF inhibitors and other immune-suppressive biologics have become the standard …
Laurie Ann Rumker · HARVARD MEDICAL SCHOOL · 2023 · $52,694 — Project Summary/Abstract Tuberculosis (TB) remains the global leading cause of death from an infectious agent. Understanding why some patients present with early symptoms while others develop latent infections is critical for combating this illness. While environmental factors are known to elevate …
PAUL L FOX · CLEVELAND CLINIC LERNER COM-CWRU · 2023 · $402,500 — Project Summary/Abstract Obesity is an epidemic-scale problem in the U.S. affecting about 35% of the adult population, and is a major risk factor for the ongoing pandemic, COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the RNA betacoronavirus that is the causative agent of…
PHILIP J SANTANGELO · EMORY UNIVERSITY · 2023 · $723,501 — Project Summary There are over 200 viruses known to infect humans and they contribute to 6.6% of global mortality. We have approximately 91 drugs for 10 viral species and vaccines for only 16. Reassortment and antigenic changes pose challenges to vaccine efficacy; this has clearly been demonstrated …
Ryan Englander · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2023 · $52,694 — PROJECT SUMMARY/ABSTRACT Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the United States. Immune checkpoint inhibitors (ICIs) like anti-PD-1 have increased overall survival in NSCLC, but most patients still do not respond to treatment. Cancer vaccines that target tum…
LANCE P FORD · ATTOGENE · 2023 · $229,975 — Summary/Abstract The past decade has brought an escalating growth of important new commercial applications for RNA. RNA molecules have emerged as the preeminent regulators of gene expression. They have a unique ability to edit genomes and destabilize gene products. New diagnostic applications for R…
MEGERDITCH KILEDJIAN · RUTGERS, THE STATE UNIV OF N.J. · 2023 · $33,494 — Project Summary of the funded parental grant GM126488: RNA 5′ end capping provides a layer of “epitranscriptomic” regulation, influencing numerous aspects of RNA fate, including stability, processing, localization and translatability. Furthermore, enzymes that remove RNA 5′ end caps play critical ro…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $368,909 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Monica Banez-Coronel · UNIVERSITY OF FLORIDA · 2023 · $26,239 — Project Summary Repeat expansion mutations cause more than 50 neurodegenerative diseases, including Huntington’s disease (HD) and C9orf72 amyotrophic lateral sclerosis. Despite intense research, there are no effective treatments for any of these disorders. Repeat expansion mutations are often bidire…
Jonathan Lawton · UNIVERSITY OF MARYLAND BALTIMORE · 2023 · $34,179 — PROJECT SUMMARY Despite decades of research, Plasmodium falciparum malaria continues to kill hundreds of thousands of children in sub-Saharan Africa each year. Vulnerability to severe malaria is complex, involving both host and parasite factors. Blood type A is an established risk factor for severe …
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $1,381,667 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…